On October 23, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that the Company will have two presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting on November 6-10, 2019 at the Gaylord National Convention Center in National Harbor, MD (Press release, Mirati, OCT 23, 2019, View Source [SID1234542457]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation Details:
Title: Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)
Presentation Date and Time: Saturday, November 9th at 6:15pm EST – 6:30pm EST
Presenter: Pavlos Msaouel, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Abstract ID: 12620
Concurrent Session 310: Combination Phase 1-2 Clinical Trials
Location: Gaylord National Convention Center
Poster Presentation Details:
Title: Sitravatinib and nivolumab for resectable oral cavity squamous cell carcinoma window of opportunity study (SNOW)
Poster Session Date and Time Saturday, November 9th at 7:00am EST – 8:30pm EST
Presenter: Marc Oliva, M.D., Princess Margaret Hospital, University of Toronto
Poster Number: P400
Poster Presentation Hours: 12:35pm – 2:05pm and 7:00pm – 8:30pm EST on Saturday, November 9th
Location: Gaylord National Convention Center
About Sitravatinib
Sitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being evaluated in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in patients whose cancers have progressed despite treatment with a checkpoint inhibitor. Sitravatinib’s potent inhibition of TAM and split family RTKs may overcome resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment, enhancing antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are refractory to prior immune checkpoint inhibitor therapy, including the ongoing potentially registration-enabling Phase 3 trial of sitravatinib in combination with a checkpoint inhibitor in non-small cell lung cancer (NSCLC). In addition, sitravatinib combinations with checkpoint inhibitors are being evaluated in selected checkpoint inhibitor naïve patients.
Sitravatinib is also being evaluated as a single-agent in a Phase 1b expansion clinical trial emphasizing enrollment of patients whose tumors harbor specific mutations in the CBL protein. When CBL is inactivated by mutation, multiple RTKs, including TAM, VEGFR2 and KIT, are dysregulated and may act as oncogenic tumor drivers in NSCLC and melanoma.